Teva Faces Antitrust Suit Over Alleged EpiPen-Nuvigil Scheme (1)

Teva Pharmaceutical Industries Ltd. is facing federal antitrust litigation over claims that it illegally pledged to stay out of the generic EpiPen market if two competing drugmakers delayed generic versions of the narcolepsy treatment Nuvigil.

The lawsuit targets several affiliates of the Tel Aviv-based pharmaceutical company, one of the world’s leading manufacturers of generic drugs. It comes five months after the other two companies, Mylan NV and Pfizer Inc., paid a combined $609 million to settle similar allegations.

“But those settlements addressed only the EpiPen, and only Mylan and Pfizer’s roles,” according to the proposed class action filed Dec. ...